FDA Review Document and New Toxicological Sciences Publication Detail Results
![Simulations Plus to Present at the LD 500 Virtual Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at the LD 500 Virtual Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical...
![Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and..
![Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products...
![Simulations Plus Announces Proposed Underwritten Public Offering](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Announces Proposed Underwritten Public Offering
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and...
![Simulations Plus Reports Third Quarter FY2020 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Third Quarter FY2020 Financial Results
Third Quarter and 9MoFY20 Revenues Grow 24%
![Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, July 9, 2020, at 4:15 PM ET
![Simulations Plus Receives New Grant Award from the FDA](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Receives New Grant Award from the FDA
Novel PBPK/PD modeling strategies for ophthalmic drug products will inform regulatory decision-making
![Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference
![Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery...
![U.S. FDA Renews Annual DILIsym Software Licenses](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
U.S. FDA Renews Annual DILIsym Software Licenses
FDA Maintains Access to Leading Liver Injury Software Program
![Simulations Plus Reports Record Second Quarter FY2020 Revenue](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Record Second Quarter FY2020 Revenue
Quarterly Revenues Up 22%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share
![Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®
Updated Functionality Seamlessly Integrates Mechanistic Modeling in Drug Discovery
![Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET
![Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe
Accretive acquisition adds Monolix Suite, a population PKPD modeling solution for pharmacometricians
![Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET
![Simulations Plus Offers Rapid Response COVID-19 Research Initiative](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Offers Rapid Response COVID-19 Research Initiative
New StrategiesPlus™ program created for collaborative research acceleration
![Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team
Simulations Plus today announced the addition of Sandra Suarez-Sharp as Vice President, Regulatory Affairs to lead the new Regulatory Strategies team.
20-year FDA Master Reviewer will advise the planning of drug development programs with sponsor companies
![DILIsym Services Partners with Large Pharmaceutical Company to Begin QSP Model Development for Heart Failure](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
DILIsym Services Partners with Large Pharmaceutical Company to Begin QSP Model Development for Heart Failure
QSP Modeling Project Targeted at Prevention of Heart Failure
![Simulations Plus to Present at the 22nd Annual Needham Growth Conference](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at the 22nd Annual Needham Growth Conference
Simulations Plus to Present at the 22nd Annual Needham Growth Conference